Neurosoft Bioelectronics, a neurotechnology company developing scalable and minimally
invasive brain-computer interfaces (BCIs), has raised $7.5 million in an
oversubscribed seed funding round led by Skybound Venture Capital, with
participation from Protocol Labs, IAG Capital Partners and Connecticut
Innovations, among others. The latest financing brings the company’s total
funding to more than $20 million.
Headquartered
in Switzerland with operations in New York, Neurosoft Bioelectronics is
developing a platform designed to provide access to the full cortex without
penetrating brain tissue. Its proprietary soft and stretchable electrodes are
significantly more compliant than conventional neural interfaces and are
intended to support broader cortical coverage through minimally invasive
procedures.
The company
says its long-term objective is to build a large-scale neural data platform
capable of supporting foundation models of the human cortex. According to
Neurosoft, data collected through its implantable devices could help improve
the performance of both invasive and non-invasive brain-computer interfaces
over time.
Nicolas Vachicouras, PhD, said the company’s soft electrode technology and regulatory
approach enable Neurosoft to collect neural data at a scale and quality that is
difficult to achieve safely with existing alternatives, adding:
That data
is the foundation for improved clinical outcomes, and a cortical foundation
model that will help shape the next generation of brain interfaces. The
investor support we’ve seen in this round validates that we’re on the right
path.
To date,
Neurosoft has tested its technology in 10 patients across two ongoing clinical
trials at UTHealth Houston and UMC Utrecht, including a 64-channel soft brain
interface study for epilepsy surgery guidance. The company says its technology
portfolio includes more than 25 patents and over 25 peer-reviewed scientific
publications.
With the new
funding, Neurosoft Bioelectronics plans to advance its clinical and commercial
milestones, including demonstrating minimally invasive deployment in human
patients and progressing toward US commercialisation of its first brain
interface product.